Boston-based Bicara launched in 2021 and is a subsidiary of Indian pharma company Biocon, which provided its seed funding. Bicara is also studying ficerafusp alfa, its lead candidate, in anal cancer ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Gardasil shipment pause, weak guidance, and looming Keytruda risks send investors scrambling--can Merck turn things around?

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

Merck's stock tumbled 11.8% Tuesday, putting it on track for its biggest one-day selloff in almost 17 years, after the drug company's softer-than-expected guidance amid struggles for its HPV vaccine ...

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded. [Operator instructions] I would now like to turn the call over to Mr. Peter ...

Merck (NYSE:MRK) is scheduled to announce Q4 earnings results on Tuesday, February 4th, before market open. Truist Securities ...

Keytruda and Lenvima with chemotherapy improved progression-free survival and objective response rate but not overall survival in HER2-negative gastroesophageal adenocarcinoma. The safety profile of ...

A global phase 3 trial is evaluating ASP-1929 photoimmunotherapy with Keytruda for recurrent HNSCC, involving around 400 patients. ASP-1929, an antibody-dye conjugate targeting EGFR, is activated by ...

Last year wasn't a good one for Merck (NYSE: MRK), one of the largest pharmaceutical companies in the world. The healthcare giant is dealing with the fast-approaching patent cliff for its most ...

The healthcare giant is dealing with the fast-approaching patent cliff for its most important product, cancer medicine Keytruda. Further, even beyond Keytruda's upcoming loss of patent exclusivity in ...